TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00371189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Description: Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10\^8 viral particles (vp)/mL, 10\^9 vp/mL, 10\^10 vp/mL and 10\^11 vp/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Description: Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10\^8 viral particles (vp)/mL, 10\^9 vp/mL, 10\^10 vp/mL and 10\^11 vp/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Description: Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10\^8 viral particles (vp)/mL, 10\^9 vp/mL, 10\^10 vp/mL and 10\^11 vp/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Description: Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10\^8 viral particles (vp)/mL, 10\^9 vp/mL, 10\^10 vp/mL and 10\^11 vp/mL.
Study: NCT04557267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose
Description: Dosage 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle-dose
Description: Dosage 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher-dose
Description: Dosage 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04651140

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks
Study: NCT04161053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 550 mg twice daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500 mg twice daily for 6 months
Study: NCT02344264

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.
Study: NCT02541617

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Deep Brain Stimulator will be programmed with at the implanting movement disorders center
Study: NCT03054051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tumaini Mobile Phone Game
Description: Tumaini is a scenario-based role-playing game application, optimized for use on low-cost Android smartphones. Participants will be invited to play the game for at least ten hours over a period of three weeks. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma and harmful gender norms; and promote parent-child dialogue.
Study: NCT03937518

Intervention type: DRUG
Group type: OTHER
Intervention: Strontium Ranelate
Description: Patients received strontium ranelate 2gm (one sachet daily with 50 ml water at bedtime at least 2 h after food), as the compliance of patient assessed by counting number of sachet that patient returns at every visit and safety is assessed by recording adverse effects as blood pressure and heart rate every visit and patients received physiotherapy program in the form of (US therapeutic acoustic radiation and exercise program) 3 times per week for 6 months.~Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min (

Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min (Medserve, England) (Huang et al., 2001). Patients were positioned in a supine position with the affected knee flexed at 90° and the sound head was held stationary over the tibiofemoral joint medial to the patellar tendon to enhance energy penetration into the joint space (White et al., 2007).~Exercise program:~The subjects were treated with a group-exercise program composed of a range of motion of all lower limb and 45 min strengthening exercises with 5 min stretching exercises of lower limb muscles 3 times per week under the supervision of the same physiatrist (Fitzgerald and Oatis

Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min (Medserve, England) (Huang et al., 2001). Patients were positioned in a supine position with the affected knee flexed at 90° and the sound head was held stationary over the tibiofemoral joint medial to the patellar tendon to enhance energy penetration into the joint space (White et al., 2007).~Exercise program:~The subjects were treated with a group-exercise program composed of a range of motion of all lower limb and 45 min strengthening exercises with 5 min stretching exercises of lower limb muscles 3 times per week under the supervision of the same physiatrist (Fitzgerald and Oatis
Study: NCT01207947

Intervention type: DRUG
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: Patients under daily life treatment receiving Levitra according to local drug information.
Study: NCT04216147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE
Description: Percutaneous Needle Electrolysis: the application of galvanic current through an acupuncture needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for CTS
Description: Median nerve release
Study: NCT02590666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar Polypectomy
Description: Polyps resection with bipolar electrode

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Polypectomy
Description: Polyps resection with microscissors or graspers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar electrode
Description: Bipolar electrode used to performs polypectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microscissors or graspers
Description: Mechanical instruments used to performs polypectomy
Study: NCT02718664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (breakfast)
Description: Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
Study: NCT03132545

Intervention type: DIAGNOSTIC_TEST
Intervention: SenseWear Armband (SWA) monitoring
Description: Participants wore the SWA on their right arm

Intervention type: DIAGNOSTIC_TEST
Intervention: SenseWear Armband (SWA) monitoring
Description: Participants wore the SWA on their right arm

Intervention type: DIAGNOSTIC_TEST
Intervention: total body dual-energy X-ray absorptiometry
Description: DEXA was used to estimate abdominal visceral adipose tissue and subcutaneous adipose tissue

Intervention type: DIAGNOSTIC_TEST
Intervention: total body dual-energy X-ray absorptiometry
Description: DEXA was used to estimate abdominal visceral adipose tissue and subcutaneous adipose tissue
Study: NCT02060500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiaplication
Study: NCT03540264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil Majesty TM
Description: Tooth wear - composite resin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vita-Enamic®
Description: Tooth wear - polymer-infiltrated-ceramic-network
Study: NCT04758806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbial transplantation
Description: Procured faeces procured from unrelated donor
Study: NCT04477369

Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1439
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1439
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1439
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1464
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1464
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1464
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWC202003
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWC202003
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWC202003
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWC202004
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWC202004
Description: 300mg single dose

Intervention type: DRUG
Group type: OTHER
Intervention: DWC202004
Description: 300mg single dose
Study: NCT00993551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary surgery for cleft palate
Description: Surgery completed using the Sommerlad technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary surgery for cleft palate
Description: Surgery completed using the Sommerlad technique
Study: NCT00761228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine
Description: Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a continues subcutaneous infusion of saline solution.
Study: NCT03432481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicompartmental Knee Arthroplasty Surgery
Description: Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bodycad Unicompartmental Knee System (BUKS)
Description: Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
Study: NCT02566057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGx testing guided treatment (PGT)
Description: Genecept Assay (GeneceptTM Assay) will provide information on genotypes of genetic variants that are relevant to psychiatric drug response. The provider can use the information to decide on which psychotropic drugs to use.
Study: NCT00352326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reprogramming assisted communication device interface
Description: The subjects were required to touch targets on the iPad® screen with the index finger of their preferred (less-affected) arm. The experimental task consisted of 180 targets divided in 4 blocks: 45 targets each block with a 1-minute interval between trials to avoid fatigue. Targets appeared at 1 of 9 different locations on the screen, and subjects moved their finger sequentially from one target to the next.
Study: NCT02961439

Intervention type: BEHAVIORAL
Intervention: Epworth Richmond's Echocardiography Focused Year
Description: a year long echo teaching program
Study: NCT04263168

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous Glucose monitoring in the perioperative period
Description: All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Continuous Glucose monitoring in the perioperative period
Description: All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
Study: NCT04447105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: total intravenous anesthesia with propofol
Description: In the TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using infusion pump (Orchestra®; Fresenius Vial, Brezins, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhalation anesthesia with desflurane
Description: In the desflurane group, anesthesia is induced with propofol 1-2 mg/kg and maintained with desflurane (5-7 vol %). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
Study: NCT00085553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study: NCT01581177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol DPI 25 mcg/inh
Description: Albuterol DPI with 25 mcg Albuterol/inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol DPI 25 mcg/inh
Description: Albuterol DPI with 25 mcg Albuterol/inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol DPI 90 mcg/inh
Description: Albuterol DPI with 90 mcg Albuterol/inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol DPI 90 mcg/inh
Description: Albuterol DPI with 90 mcg Albuterol/inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Placebo DPI with 0 mcg Albuterol/inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DPI
Description: Placebo DPI with 0 mcg Albuterol/inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DPI
Description: Placebo DPI with 0 mcg Albuterol/inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol MDI 90 mcg/inh
Description: Albuterol MDI with 90 mcg Albtuerol/inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol MDI 90 mcg/inh
Description: Albuterol MDI with 90 mcg Albtuerol/inhalation
Study: NCT02144792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C] -verapamil PET
Description: While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C] -verapamil PET
Description: While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C] -verapamil PET
Description: While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.
Study: NCT00545753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinosad
Description: 10 minute topical application product, following by a complete rinse off.
Study: NCT03292510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GO-OUT Group
Description: Following a baseline assessment, eligible participants will be stratified by site, and randomly assigned to receive the 1-day educational workshop and 3-month outdoor mobility program (GO-OUT intervention). Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop Group
Description: the 1-day workshop plus reminders. Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline
Study: NCT00503893

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.

Intervention type: OTHER
Intervention: Blood specimen
Description: Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.
Study: NCT04771845

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: Magnetic stimulation to alter neural activity

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: Magnetic stimulation to alter neural activity
Study: NCT00026091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04414852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: All the subjects will be administrated with 250mg apatinib on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: All the subjects will be administrated with 250mg apatinib on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib Mesylate
Description: All the subjects will be administrated with 250mg apatinib on day 1
Study: NCT01534273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT03487770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Oral Solution
Description: Aripiprazole 2\~15 mg/day (2\~15 mL/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: Placebo 2\~15 mg/day (2\~15 mL/day)
Study: NCT02067520

Intervention type: DRUG
Group type: OTHER
Intervention: intrathecal hydromorphone (IT hydromorphone)
Study: NCT04294537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: At the end of surgery patients will receive bilateral ultrasound-guided single-shot TAP block: 0,15% levobupivacaine 0,75 mg/kg per side will be injected between internal oblique and transveralis fascia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIA local infiltration
Description: At the end of surgery 0,5% levobupivacaine 1.5 mg/kg, equally distributed between ports, injected in the skin and subcutaneous tissue during wound closure.
Study: NCT00545753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinosad
Description: 10 minute topical application followed by a complete rinse off, followed by a nit combing regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 1%
Description: Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
Study: NCT03442153

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solgar No7 Complex
Description: Solgar No7 Capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets Cellulose
Study: NCT04174703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-compassionate letter-writing intervention
Description: Participants in this condition will be asked to engage in an online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks.